A Study of Language Interpretation Solutions for People With Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do not speak Spanish/Mandarin). In Phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.
Eligibility criteria
Qualifiers
Age >=18 years (per EMR)
Preferred language for healthcare is Spanish or Mandarin (per self-report)
Limited English Proficient; cannot speak English "very well" (per self-report)
Diagnosis of breast cancer or gastrointestinal (per EMR)
Disqualifiers
Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient's care team, or study team)
Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team)
None
None
Trial design
Treatments tested in this trial
- Remote Simultaneous Medical Interpreting/RSMI
- Remote Consecutive Medical Interpreting/RCMI
- Remote Consecutive Video Medical Interpreting/RCVI
Treatment groups
700 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov